Stockreport

Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

Cyclacel Pharmaceuticals, Inc.  (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations
PDF BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutic [Read more]